(Q27691299)

Alexander RE

2

1 reference

Maclennan GT

3

1 reference

Cummings OW

4

1 reference

Montironi R

5

1 reference

Lopez-Beltran A

6

1 reference

Cramer HM

7

1 reference

Davidson DD

8

1 reference

Zhang S

9

1 reference

publication date

March 2012

1 reference

1 reference

25

1 reference

issue

3

1 reference

page(s)

347-69

1 reference

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The landscape of EGFR pathways and personalized management of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Impact of EGFR mutation analysis in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR signaling and drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor (EGFR) signaling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Discovery of selective irreversible inhibitors for EGFR-T790M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Structure and clinical relevance of the epidermal growth factor receptor in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Evidence for common clonal origin of multifocal lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR mutation and response of lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Molecular analysis-based treatment strategies for the management of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Visualization of FISH Probes by dual-color chromogenic in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The biology of epidermal growth factor receptor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR-mutated lung cancer: a paradigm of molecular oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

KRAS and BRAF: drug targets and predictive biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Clinical implications of MET gene copy number in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Adenosquamous carcinoma of the lung: a microdissection study of KRAS and EGFR mutational and amplification status in a western patient population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Correlation of genes associated with drug response to prognosis of large cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Anaplastic lymphoma kinase: signalling in development and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Targeting anaplastic lymphoma kinase in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

ALK, lung cancer, and personalized therapy: portent of the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The biology and treatment of EML4-ALK non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor: mechanisms of activation and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Monoclonal antibodies as effective therapeutic agents for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The molecular pathology of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Raf kinases: function, regulation and role in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

The histopathology of BRAF-V600E-mutated lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Organization of the human hepatocyte growth factor-encoding gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Novel therapeutic inhibitors of the c-Met signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone r

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

Mechanisms of tumor resistance to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021

PIK3CA mutation status in Japanese lung cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.215

7 January 2021